| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S15365 R63208 |
Bromley (Carbamazepine) (Epilepsy) (Controls exposed to LTG), 2023 | Preterm birth (gestational age < 37 weeks) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.76 [0.20;2.84] C excluded (control group) |
3/27 15/106 | 18 | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15366 R63221 |
Bromley (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 | Preterm birth (gestational age < 37 weeks) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.78 [0.20;3.05] C | 3/27 11/80 | 14 | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8082 R24678 |
Aydin (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020 | Preterm delivery (before 37 weeks of gestation) | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.60 [0.11;62.58] C excluded (control group) |
2/15 0/7 | 2 | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8074 R24626 |
Aydin (Carbamazepine) (Controls unexposed, sick), 2020 | Preterm delivery (before 37 weeks of gestation) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 1.54 [0.19;12.32] C | 2/15 2/22 | 4 | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10075 R36692 |
Coste (Carbamazepine), 2020 | Gestational age at birth (< 37 WA) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick | Adjustment: No | 0.81 [0.41;1.63] C | 9/176 131/2,108 | 140 | 176 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8145 R25042 |
Cohen (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2019 | Preterm birth (ICD-9 644.2, 774.2, 776.6, 362.20, 362.22, 362.27, 765 excluding 765.20, 765.29) | early pregnancy | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
1.24 [0.78;1.96] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8141 R25014 |
Cohen (Carbamazepine) (Controls unexposed NOS), 2019 | Preterm birth (ICD-9 644.2, 774.2, 776.6, 362.20, 362.22, 362.27, 765 excluding 765.20, 765.29) | early pregnancy | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 0.84 [0.59;1.18] | -/- 160,604/1,440,631 | 160,595 | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6253 R16654 |
Arkilo (Carbamazepine), 2015 | Premature delivery | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 3.52 [0.68;18.07] C | 5/14 3/22 | 8 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5925 R15071 |
Artama (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013 | Preterm birth (<37 gestational weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.17 [0.55;2.50] C excluded (control group) |
58/1,077 8/173 | 66 | 1,077 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5909 R14886 |
Artama (Carbamazepine) (Controls unexposed, disease free), 2013 | Preterm birth (<37 gestational weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
1.32 [1.01;1.72] excluded (control group) |
58/1,077 30,027/719,509 | 30,085 | 1,077 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5917 R14982 |
Artama (Carbamazepine) (Controls unexposed, sick), 2013 | Preterm birth (<37 gestational weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.13 [0.80;1.60] | 58/1,077 85/1,793 | 143 | 1,077 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6356 R21027 |
Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) b, 2013 | Preterm delivery (< 37 weeks) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.87 [0.24;3.10] C excluded (control group) |
4/67 7/103 | 11 | 67 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6354 R17337 |
Veiby (Carbamazepine) (Controls unexposed, disease free) b, 2013 | Preterm delivery (< 37 weeks) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
0.80 [0.30;2.30] excluded (control group) |
4/67 7,269/106,899 | 7,273 | 67 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6355 R17333 |
Veiby (Carbamazepine) (Controls unexposed, sick) b, 2013 | Preterm delivery (< 37 weeks) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.75 [0.26;2.21] C | 4/67 30/386 | 34 | 67 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5511 R17486 |
Pennell (Carbamazepine), 2012 | Preterm Birth (< 37 weeks GA) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.85 [0.64;5.30] C | 10/93 6/98 | 16 | 93 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6941 R19600 |
Cummings (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2011 | Preterm (35-37 weeks) | throughout pregnancy | retrospective cohort (registry) | exposed to other treatment, sick excluded | Adjustment: No |
0.53 [0.13;2.15] C excluded (control group) |
4/49 5/35 | 9 | 49 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6939 R19596 |
Cummings (Carbamazepine) (Controls unexposed, disease free), 2011 | Preterm (35-37 weeks) | throughout pregnancy | retrospective cohort (registry) | unexposed, disease free | Adjustment: No | 8.80 [0.46;168.35] C | 4/49 0/44 | 4 | 49 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6188 R16299 |
Nadebaum (Carbamazepine), 2011 | Born premature (<37 wk) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.78 [0.03;21.03] C | 1/34 0/9 | 1 | 34 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6424 R17672 |
McVearry (Carbamazepine), 2009 | Premature birth | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 6.11 [0.27;138.46] C | 2/16 0/17 | 2 | 16 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8220 R25726 |
Endo (Carbamazepine) (Controls unexposed, disease free), 2004 | Preterm delivery (< week 37) | throughout pregnancy | retrospective cohort | unexposed, disease free excluded | Adjustment: No |
2.12 [0.41;11.09] C excluded (control group) |
2/7 104/656 | 106 | 7 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8223 R25771 |
Endo (Carbamazepine) (Controls unexposed, sick), 2004 | Preterm delivery (< week 37) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 0.56 [0.01;37.57] C | 2/7 0/1 | 2 | 7 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5578 R14510 |
Diav-Citrin (Carbamazepine), 2001 | Premature infants (week < 37) | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No Matched | 2.41 [0.90;6.48] C | 9/91 8/184 | 17 | 91 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6823 R19287 |
Van der Pol (Carbamazepine) (Controls unexposed, disease free), 1991 | Gestational age (≤ 37 wk) | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
0.53 [0.03;10.70] C excluded (control group) |
0/11 4/55 | 4 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6825 R19337 |
Van der Pol (Carbamazepine) (Controls unexposed, sick), 1991 | Gestational age (≤ 37 wk) | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 0.37 [0.02;8.48] C | 0/11 2/22 | 2 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 14 studies | 1.05 [0.85;1.29] | 160,982 | 1,677 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Carbamazepine) (Epilepsy) (Controls unexposed, sick; 2: Carbamazepine) (Controls unexposed, sick; 3: Carbamazepine; 4: Carbamazepine) (Controls unexposed NOS; 5: Carbamazepine; 6: Carbamazepine) (Controls unexposed, sick; 7: Carbamazepine) (Controls unexposed, sick) ; 8: Carbamazepine; 9: Carbamazepine) (Controls unexposed, disease free; 10: Carbamazepine; 11: Carbamazepine; 12: Carbamazepine) (Controls unexposed, sick; 13: Carbamazepine; 14: Carbamazepine) (Controls unexposed, sick;
Asymetry test p-value = 0.1762 (by Egger's regression)
slope=-0.1166 (0.1514); intercept=0.5482 (0.3814); t=1.4371; p=0.1762
excluded 6823, 8220, 6941, 5925, 5909, 6356, 6354, 8145, 8082, 15365